Skip to main content

Table 2 Baseline characteristics and demographics

From: Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Baseline Characteristics

Exenatide (N = 2,316)

Pooled Comparator (N = 1,629)

Gender, M/F (%)

56/44

53/47

Race (%)

  

   Caucasian

64

65

   Black

6

4

   Hispanic

11

10

   Asian

19

20

   Other

1

1

Age (years)

56 ± 10

56 ± 10

   ≥65 years (%)

21

20

Duration of Diabetes (years)

8 ± 6

8 ± 6

   ≥10 years (%)

32

35

Weight (kg)

89.1 ± 20.3

87.8 ± 19.8

Body Mass Index (BMI [kg/m 2 ])

31.5 ± 5.6

31.3 ± 5.4

   BMI <30 kg/m2 (%)

44

45

   BMI ≥30 kg/m2 (%)

56

55

HbA 1c (%)

8.33 ± 1.06

8.38 ± 1.07

Systolic Blood Pressure (SBP [mm Hg])

131 ± 4

132 ± 5

Diastolic Blood Pressure (DBP [mm Hg])

79 ± 2

79 ± 1

Heart Rate (beats per minute)

75 ± 9

75 ± 9

Renal Function Impairment* (%)

  

   None

86

86

   Mild

13

14

   Moderate

1

1

  1. Data are mean ± SD unless otherwise noted. Percentages may not add to 100 due to rounding
  2. * Renal function is defined based on creatinine clearance (CrCl) as calculated by the Cockcroft-Gault equation: normal, CrCl >80 mL/min; mild impairment, CrCl >50-80 mL/min; moderate impairment, CrCl >30-50 mL/min